RVPH Stock Analysis: Buy, Sell, or Hold?
RVPH - Reviva Pharmaceuticals Holdings, Inc. Common Stock
$0.35
-0.44 (-55.73%)
▼
5d:
-60.0%
30d:
-58.89%
90d:
+33.57%
WAIT
LOW Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When RVPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RVPH is down 60.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RVPH is down 60.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RVPH is currently trading at $0.35, which is considered fair based on recent price action.
Technical Outlook: Technically, RVPH is in a strong downtrend. Immediate support is located at $0.26, while resistance sits at $0.91. Short-term momentum is weak, with the stock down 55.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.20 (+16429.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RVPH is in a strong downtrend. Immediate support is located at $0.26, while resistance sits at $0.91. Short-term momentum is weak, with the stock down 55.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.20 (+16429.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
45/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-55.7%)
- BULLISH: Trading 16429.4% below Wall St target ($58.20)
- WARNING: Recommendation downgraded due to -60.0% 5-day decline - wait for stabilization
Support & Resistance Levels
Support Level
$0.26
Resistance Level
$0.91
Current Trend
Strong Downtrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.37
Wall Street Target
$58.20
(+16429.4%)
Share & Embed Analysis
Last updated: June 24, 2026 11:28 AM ET
Data refreshes hourly during market hours. Next update: 12:28 PM
Data refreshes hourly during market hours. Next update: 12:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RVPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
